Filing Analysis
Protalix BioTherapeutics, Inc. filed a Form 8-K to announce that it has posted its May 2026 corporate presentation to its website.
📋 Key Facts
- On May 21, 2026, the company posted its corporate presentation to its website.
- The presentation is furnished as Exhibit 99.1 to the Current Report.
- The filing is submitted under Item 7.01 (Regulation FD Disclosure) and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Protalix BioTherapeutics announced its financial results for the first quarter ended March 31, 2026, along with business and clinical updates. The information was provided via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Announced financial results for the fiscal quarter ended March 31, 2026
- Provided a business and clinical update in the accompanying press release (Exhibit 99.1)
- The report was filed under Item 2.02, Results of Operations and Financial Condition
- The filing date is May 13, 2026
Protalix BioTherapeutics announced its financial results for the fiscal year ended December 31, 2025, and provided a business and clinical update.
📋 Key Facts
- The filing was made on March 18, 2026, to report results for the fiscal year ended December 31, 2025.
- The company furnished a press release as Exhibit 99.1 containing the financial data and clinical updates.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Protalix BioTherapeutics announced that the European Commission has approved a new 2 mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® (pegunigalsidase alfa). This approval provides an additional dosing option for adults living with Fabry disease who are stable on Enzyme Replacement Therapy.
📋 Key Facts
- On March 9, 2026, the European Commission (EC) approved a 2 mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio®.
- The approval is specifically for adults living with Fabry disease who are stable with an Enzyme Replacement Therapy (ERT).
- The EC decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
- Elfabrio® is being commercialized in partnership with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A.